[{"id":"5d9e65c6-b900-41df-834e-6e18a16cdf9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470203","created_at":"2026-03-28T01:44:18.552Z","updated_at":"2026-03-28T01:44:18.552Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT07470203","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/31/2026","start_date":" 03/31/2026","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"9ff75a13-e0fb-4659-a12b-a20b35ef7bb8","acronym":"FLAMINGO-01","url":"https://clinicaltrials.gov/study/NCT05232916","created_at":"2022-02-10T14:52:54.352Z","updated_at":"2025-02-25T13:40:51.671Z","phase":"Phase 3","brief_title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects","source_id_and_acronym":"NCT05232916 - FLAMINGO-01","lead_sponsor":"Greenwich LifeSciences, Inc.","biomarkers":" HER-2 • HLA-A","pipe":" | ","alterations":" HLA-A*02 positive","tags":["HER-2 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • GLSI-100 • GP2"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"b6ca3d93-c186-4751-9a4a-5de77d5b1a3b","acronym":"MOUNTAINEER-03","url":"https://clinicaltrials.gov/study/NCT05253651","created_at":"2022-02-24T14:52:50.182Z","updated_at":"2025-02-25T13:36:05.619Z","phase":"Phase 3","brief_title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05253651 - MOUNTAINEER-03","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" RAS wild-type","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/24/2022","start_date":" 10/24/2022","primary_txt":" Primary completion: 04/03/2026","primary_completion_date":" 04/03/2026","study_txt":" Completion: 07/27/2029","study_completion_date":" 07/27/2029","last_update_posted":"2025-02-21"},{"id":"16a15023-befe-4ca0-9aaa-23efe0cc2225","acronym":"MK-7119-001","url":"https://clinicaltrials.gov/study/NCT04721977","created_at":"2021-01-25T15:53:18.932Z","updated_at":"2025-02-25T13:49:04.272Z","phase":"Phase 2","brief_title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","source_id_and_acronym":"NCT04721977 - MK-7119-001","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 11/25/2025","study_completion_date":" 11/25/2025","last_update_posted":"2025-02-20"},{"id":"9651d7d1-9259-4164-9a62-b578441ae0c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05730712","created_at":"2023-02-16T15:00:29.642Z","updated_at":"2025-02-25T12:29:24.132Z","phase":"Phase 2","brief_title":"Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05730712","lead_sponsor":"Mayo Clinic","biomarkers":" NRG1","pipe":"","alterations":" ","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/08/2024","start_date":" 03/08/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-20"},{"id":"308e274e-e2f7-4972-a5fd-9ed7015b2fc2","acronym":"HERIZON-GEA-01","url":"https://clinicaltrials.gov/study/NCT05152147","created_at":"2021-12-09T18:00:29.644Z","updated_at":"2025-02-25T14:02:38.513Z","phase":"Phase 3","brief_title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","source_id_and_acronym":"NCT05152147 - HERIZON-GEA-01","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 918","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-19"},{"id":"31764096-6379-4314-a6a8-370698657726","acronym":"","url":"https://clinicaltrials.gov/study/NCT02226276","created_at":"2021-01-18T10:26:21.550Z","updated_at":"2025-02-25T14:14:41.067Z","phase":"","brief_title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02226276","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-02-18"},{"id":"46c003c1-113b-4717-8770-727e751b80fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01093612","created_at":"2021-01-18T04:19:21.949Z","updated_at":"2025-02-25T14:14:31.640Z","phase":"","brief_title":"Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer","source_id_and_acronym":"NCT01093612","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/16/2011","start_date":" 03/16/2011","primary_txt":" Primary completion: 10/23/2018","primary_completion_date":" 10/23/2018","study_txt":" Completion: 08/26/2025","study_completion_date":" 08/26/2025","last_update_posted":"2025-02-18"},{"id":"ebc393d7-e583-45ba-8ae9-46feb62c3abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376878","created_at":"2022-05-17T12:54:20.623Z","updated_at":"2025-02-25T14:08:52.333Z","phase":"Phase 4","brief_title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","source_id_and_acronym":"NCT05376878","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/21/2022","start_date":" 12/21/2022","primary_txt":" Primary completion: 02/25/2026","primary_completion_date":" 02/25/2026","study_txt":" Completion: 02/25/2026","study_completion_date":" 02/25/2026","last_update_posted":"2025-02-18"},{"id":"b33b770e-2030-41f5-b3a0-0baa9951a5d5","acronym":"ProHer","url":"https://clinicaltrials.gov/study/NCT05415215","created_at":"2022-06-13T16:55:43.094Z","updated_at":"2025-02-25T12:28:50.312Z","phase":"Phase 3","brief_title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","source_id_and_acronym":"NCT05415215 - ProHer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 07/05/2022","start_date":" 07/05/2022","primary_txt":" Primary completion: 11/20/2024","primary_completion_date":" 11/20/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-17"},{"id":"d5e3296e-7887-47f7-a8e8-e85cdb5b5e2b","acronym":"MORPHEUS BC","url":"https://clinicaltrials.gov/study/NCT04802759","created_at":"2021-03-17T15:57:40.908Z","updated_at":"2025-02-25T12:28:00.493Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","source_id_and_acronym":"NCT04802759 - MORPHEUS BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER • CDK4","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-17"},{"id":"ea690cf4-a21c-4998-8096-bc622dfec937","acronym":"GeparPiPPa","url":"https://clinicaltrials.gov/study/NCT05306041","created_at":"2022-03-31T16:52:51.318Z","updated_at":"2025-02-25T14:16:47.877Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","source_id_and_acronym":"NCT05306041 - GeparPiPPa","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • PGR positive","tags":["HER-2 • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 01/02/2023","start_date":" 01/02/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-17"},{"id":"40d264c0-ef98-4585-8486-d32526145561","acronym":"","url":"https://clinicaltrials.gov/study/NCT06123338","created_at":"2023-11-08T22:13:20.652Z","updated_at":"2025-02-25T14:42:29.112Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","source_id_and_acronym":"NCT06123338","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-14"},{"id":"6f7d2f98-4e51-4d54-a1e2-26db7a2d980b","acronym":"BOLD-1","url":"https://clinicaltrials.gov/study/NCT02625441","created_at":"2021-01-18T12:45:30.841Z","updated_at":"2025-02-25T14:00:53.763Z","phase":"Phase 3","brief_title":"Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer","source_id_and_acronym":"NCT02625441 - BOLD-1","lead_sponsor":"Helsinki University Central Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 516","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-11"},{"id":"830f0798-1d87-4b27-be23-d2bdac97c17f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01649271","created_at":"2021-01-18T07:06:15.291Z","updated_at":"2025-02-25T15:25:12.158Z","phase":"Phase 1","brief_title":"Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.","source_id_and_acronym":"NCT01649271","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/23/2012","start_date":" 07/23/2012","primary_txt":" Primary completion: 06/23/2016","primary_completion_date":" 06/23/2016","study_txt":" Completion: 06/23/2016","study_completion_date":" 06/23/2016","last_update_posted":"2025-02-11"},{"id":"0061b93e-583a-42c0-8bd3-4e877410955f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00950742","created_at":"2021-01-18T03:41:51.942Z","updated_at":"2025-02-25T15:25:03.808Z","phase":"Phase 1","brief_title":"Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.","source_id_and_acronym":"NCT00950742","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2025-02-10"},{"id":"95c0229a-8b91-4b07-bbd8-e69278f6a209","acronym":"DESTINY-Gastric03","url":"https://clinicaltrials.gov/study/NCT04379596","created_at":"2021-01-18T21:09:02.628Z","updated_at":"2025-02-25T16:32:08.037Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","source_id_and_acronym":"NCT04379596 - DESTINY-Gastric03","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-07"},{"id":"18460073-b219-4680-b839-36cecdb58964","acronym":"CALGB-40601","url":"https://clinicaltrials.gov/study/NCT00770809","created_at":"2021-01-17T17:29:01.763Z","updated_at":"2025-02-25T16:36:00.390Z","phase":"Phase 3","brief_title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00770809 - CALGB-40601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 305","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2025-02-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"60529635-af59-4ddd-9192-b5ec25989186","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661150","created_at":"2021-01-19T20:42:55.568Z","updated_at":"2025-02-25T16:38:08.739Z","phase":"Phase 2","brief_title":"A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction","source_id_and_acronym":"NCT04661150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/12/2021","start_date":" 03/12/2021","primary_txt":" Primary completion: 05/08/2023","primary_completion_date":" 05/08/2023","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-06"},{"id":"b1b80856-36d7-4b3b-b80b-159943ef72f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329065","created_at":"2021-01-18T20:58:01.125Z","updated_at":"2025-02-25T16:44:52.494Z","phase":"Phase 2","brief_title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","source_id_and_acronym":"NCT04329065","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-06"}]